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THE ROLE OF UBIQUILIN IN AMPA RECEPTOR UBIQUITINATION AND 
PROTEASOMAL DEGRADATION 
 
OUYANG GUO 
 
 
ABSTRACT 
Ubiquilin (UBQLN) is a member of type2 ubiquitin-like (UBL) protein family 
characterized by an UBL domain at the N-terminus and an ubiquitin associated (UBA) 
domain at the C-terminus. This protein has been shown to play an important role in the 
regulation of the levels, aggregation and degradation of various neurodegenerative 
disease-associated proteins. However, the specific functions and mechanisms of UBQLN 
regulation still remain to be elucidated. In this study, we investigate the effect of UBQLN 
expression on α-Amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid receptor 
(AMPAR) degradation and the underlying molecular mechanisms. We show that 
UBQLN overexpression decreases AMPAR levels in neurons and also reduces GluA1 
expression in HEK 293T cells. Moreover, our results indicate that UBQLN can form a 
complex with GluA1, and this interaction is related to the ubiquitination of AMPARs. In 
addition, we find a higher expression of UBQLN2 in Alzheimer’s disease (AD) patient 
brains, which might be a potential pathological mechanism of GluA1 reduction in AD. 
Given the crucial effect of UBQLN in AMPAR regulation, UBQLN may play an 
important role in synaptic transmission, brain functions as well as neurodegenerative 
diseases.   
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1. INTRODUCTION 
 
1.1 Ubiquitin and the ubiquitin-proteasome system  
Ubiquitin (Ubi) is a highly conserved 76 amino acid protein that is ubiquitously 
expressed in all eukaryotes cells. It is involved in an extensive range of biological 
functions, including DNA repair, cell cycle control, transcription, and neuronal and 
muscular degradation (Finley and Chau 1991). The structure of Ubi contains seven lysine 
residues: lysine-6, lysine-11, lysine-27, lysine-29, lysine-33, lysine-48, and lysine-63. 
Each of these lysine residues can link to other Ubi molecule to form a polymeric chain. 
Both the single Ubi protein and the poly-Ubi chain can attach to a protein substrate, 
leading to protein ubiquitination (Komander et al. 2009, Komander and Rape 2012).  
The process of ubiquitination is a series of reactions catalyzed by three important 
enzymes: ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and 
ubiquitin-ligase enzyme (E3). The initial step in this process is the activation of Ubi by 
E1 through an ATP-dependent manner, which enables the Ubi to bind to protein 
substrates later. E1 first binds to Ubi and Magnesium (Mg) to form an unstable ubiquitin-
adenylate intermediate product, and then the C-terminus glycine (G76) of Ubi interacts 
with the cysteine of E1 through a thiol-ester bond. After Ubi has been activated, it is 
transferred from E1 to E2 and forms a similar bond between the cysteine of E2 and G76, 
called the conjugation step in this process. Next, E3 can specifically recognize different 
protein substrates and facilitate the ligation between Ubi and the target proteins. The 
ligation between Ubi and substrates achieved by E3 are different. Based on the structure 
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of E3 and the manners it works in the ligation step, there are two classes of E3: HECT, 
which contains the conserved homologous to E6-AP, and RING, which contains really 
interesting new gene (RING) domains (Lin and Man 2013). The cysteine residue of 
HECT E3, which has a similar function as the cysteine residue of E1 and E2, can accept 
the activated Ubi from E2, and then transfer Ubi to specific substrates. On the other hand, 
RING E3 acts more like a scaffolding protein that facilitates the ligation between Ubi and 
target substrates (Ardley and Robinson 2005). The elongation of Ubi-chain, mediated by 
certain kinds of E2s and E3s, occurs after the activation, conjugation, and ligation steps 
as described below. Depending on lysine residues of the Ubi-Ubi linkages, Ubi proteins 
can form various formations of the Ubi-chain. Different Ubi-chain assemblies may 
trigger different reactions in their further process, such as proteasomal degradation, 
lysosomal degradation, and regulation of protein interaction. For instance, lysine-48-
linked poly-Ubi-chains have been found to go through proteasome mediated degradation, 
whereas mono-Ubi or lysine-63-linked chains have been shown to lead to lysosomal 
degradation (Komander and Rape 2012).  
The ubiquitin proteasome system (UPS), widely presents in eukaryotes cells, is one 
of the most well-studied protein degradation systems, including the cytoplasm, the 
nucleus, and the endoplasmic reticulum (ER) (Tanaka and Matsuda 2014). After a protein 
substrate is tagged with an Ubi-chain, it can be recognized by the 26S proteasome where 
it can be degraded into small peptides and amino acids. The 26S proteasome is composed 
of a catalytic 20S core particle (20S CP) capped by two 19S regulatory particles (19S RP) 
at both sides. The 20S CP is a cylinder-liked protein chamber made from two outer α-
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rings and two inner β-rings, with each ring being comprised of 7 different subunits. This 
special structure contains peptide cleavage sites of β-rings inside the chamber and gate-
liked a narrow access of α-rings on both sides. The structure of 19S RP can be divided 
into a lid part and a base part. The base part directly contacts the 20S CP, while the lid 
part is believed to interact with Ubi-chains (Farras et al. 2005). Two subunits of 19S, 
Rpn10 and Rpn13, contain an Ubi interacting motif (UIM) and can interact with Ubi-
chains and/or ubiquinated substrates.  
The 26S proteasome not only directly binds to the Ubi-chain by intrinsic Ubi 
binding domain of 19S RP, but also receives ubiquinated substrates delivered by other 
proteins. There are many shuttling factors that function as extrinsic ubiquitin receptors, 
including ubiquilin (UBQLN), which will be further discussed later in detail, and p62, 
which can indirectly recruit many substrate proteins to the 26S proteasome for 
degradation (Farras et al. 2005, Miller and Gordon 2005).  
Protein ubiquitination and degradation are highly dynamic and reversible. E1, E2, 
and E3 trigger and induce the ubiquitination of protein for further degradation, while 
another group of enzymes, deubiquitinating enzymes (DUBs), remove the Ubi-chain 
from substrates by hydrolyzing the isopeptide bond (Komander et al. 2009). So far, there 
are five families that have been categorized based on their catalytic domains: ubiquitin C-
terminal hydrolases, ubiquitin-specific proteases (USPs), ovarian tumor proteases, 
Josephins, and JAB1/ MPN/MOV34 metalloenzymes. DUBs not only cleave the bonds 
between Ubi proteins, but they also remove the whole Ubi-chain from substrates. In 
addition, they help recycle the free Ubi from unattached Ubi-chains that has been 
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removed from target proteins. By maintaining a balance between ubiquitination and 
deuibiquitination, DUBs plays important roles in a variety of physiological functions, 
including the regulation of protein stability, ubiquitin homeostasis, and the regulation of 
ubiquitin signaling. It is believed that DUBs have the specificity to recognize different 
cleavage sites as well as specific ubiquitinated substrates (Komander et al. 2009).  
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Fig. 1 This illustration shows the process of ubiquitination and proteasomal degradation. 
The ubiquitination process includes three main steps: activation, conjugation, and ligation, 
which are catalyzed by E1, E2, and E3 enzymes, respectively. Once Ubi is attached to the 
substrate, additional Ubi molecules can be added to form an Ubi-chain. Substrates tagged 
with Ubi-chains are often targeted to the 26S proteasome and subsequently degraded. 
Some ubiquitinated proteins can directly interact with subunits on the proteasome via 
their Ubi-chains, while other substrates are carried by shuttling factors to the proteasome 
for degradation. As the ubiquinated protein is carried to the proteasome, the 26S 
proteasome utilize ATP to digest the protein into small peptide fragments and release free 
Ubi proteins. In additional, DUBs can also hydrolyze isopeptide bonds within Ubi-chains 
or between Ubi-chain and its substrate, returning proteins to their original state.  
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1.2 Ubiquitin-like protein family and ubiquilin  
The family of ubiquitin-like (UBL) proteins plays an important role in many 
aspects of cellular functions, especially in the regulation of the ubiquitin-dependent 
proteasomal degradation of proteins. These proteins can be classified into two types, type 
1 and type 2, based on their structures. Type 1 UBL proteins, such as SUMO and Nedd8, 
are small proteins that have similar properties with Ubi. Although type 1 UBL proteins 
can interact with substrates through their C-terminal glycine residue like Ubi does, the 
functions are quite different from Ubi (Walters et al. 2004). Type 2 UBL proteins are 
characterized by a UBL domain at the N-terminus, which cannot interact with substrates 
directly like type 1 UBL proteins. However, increasing evidence has shown that type 2 
UBL proteins play important roles in Ubi-dependent proteolysis by interacting with many 
components including Ubi-chains, E3 ligases, and the 26S proteasome (Kleijnen et al. 
2000, Ko et al. 2004, Zhang et al. 2014).  
Ubiquilin (UBQLN) is a member of type 2 UBL proteins, characterized by a UBL 
domain at the N-terminus and an UBA domain at the C-terminus. Early studies have 
identified four kinds of UBQLN (UBQLN1-4). UBQLN1, UBQLN2 and UBQLN4 are 
highly conservative and are widely expressed in humans, mice and rats, while UBQLN3 
is testis-specific found in both humans and mice. Recently, a fifth UBQLN gene, called 
UBQLNL, has been found in humans. In a recent study, Marin investigated the 
expression levels and distribution of different UBQLN genes and proteins. The study 
showed higher levels of expression of UBQLN1 and UBQLN2 in most tissues than the 
other UBQLNs. While UBQLN1 has been shown to distribute broadly and evenly in 
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most organs, UBQLN2 has higher expression in the nervous system, especially in the 
hypothalamus, cerebral cortex, and cerebellum. UBQLN3 has a significant high level in 
testis but not in other tissues, whereas the expressions of UBQLN4 and UBQLNL are 
very low and are evenly distributed across most organs. Most current studies have 
investigated the functions of UBQLN1 and UBQLN2, but the roles of UBQLN3, 
UBQLN4, and UBQLNL are largely unknown (Marin 2014).  
UBQLN1 and UBQLN 2 have 79% similarity in their structures. UBQLN2 
possesses a collagen-liked domain, which is absent in UBQLN1 (Fig.2). Although the 
roles of UBQLN have not yet been fully understood, the high level homology between 
UBQLN1 and UBQLN2 suggests some shared functions (Zhang et al. 2014). Extensive 
research has demonstrated the crucial role of UBQLN1 and UBQLN2 in many biological 
pathways, and the two characterized domains, the UBL and UBA domains, seem to be 
essential to their functions. The UBL domain in UBQLN can form complexes with 
several subunits of the 26S proteasome such as Rnp1 and Rpn2 (Elsasser et al. 2002, 
Walters et al. 2004, Wang and Monteiro 2007), while a mutation of UBQLN without 
UBL domain cannot interact with subunits of proteasome (Ko et al. 2004). On the other 
hand, the UBA domain has been shown to interact with Ubi-chain. This interaction may 
be due to specific residues of this domain that are identified in many other ubiquitination 
related protein such as E2 and E3. In addition, a mutant of UBQLN lacking an UBA 
domain prevents its binding to Ubi-chains, indicating that the UBA domain is necessary 
for this interaction between UBQLN and Ubi-chain (Ko et al. 2004). UBQLN has also 
been shown to interact with some members of the E3 family like E6AP (Kleijnen et al. 
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2000).  
These studies suggest that UBQLN can interact with many components in the UPS, 
including Ubi-chains, E3 ligases, and the 26S proteasome, indicating that UBQLN may 
play a crucial role in the regulation of protein degradation through an Ubi-dependent 
pathway.  
 
 
 
Fig. 2 This illustration shows the structure of UBQLN1 and UBQLN2. Green and red 
boxes indicate the UBL and UBA domains, respectively. The shadowed box indicates the 
collagen-like domain in UBQLN2, which is absent in UBQLN1.  
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1.3 AMPARs proteasomal degradation  
α-Amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid receptors (AMPARs) are 
composed of four subunits, GluA1, GluA2, GluA3, and GluA4 (Kwak and Weiss 2006). 
Four subunits assemble to make up different combinations and to form the ligand-gated 
glutamatergic ionic channels. Assembling varies in different stages of the central nervous 
system (CNS) development as well as in different brain regions (Shepherd and Huganir 
2007). In the CNS, AMPARs mediates most of excitatory synaptic transmission. The 
expression of AMPARs at synaptic membranes are involved in synaptic plasticity and 
higher brain functions such as learning and memory (Lin et al. 2011). A stable amount of 
and proper compositions of AMPARs are important in maintaining normal brain 
functions, including long-term potentiation (LTP), long-term depression (LTD) and 
homeostatic synaptic plasticity (Turrigiano 2008, Zhang et al. 2009). Failure in regulation 
of AMPAR expression and distribution can result in many brain dysfunctions and 
neuronal diseases (Rodrigues et al. 2016). Although AMPARs have been considered to 
play an integral role in many brain functions, the specific mechanisms of this regulation 
still remain unclear.  
In recent years, the ubiquitination and proteasomal degradation has been shown to 
be an important process involved in many aspects of AMPAR regulation, including 
AMPAR trafficking, localization, and internalization. The first model that indicates the 
ubiquitination of APMRAs is in C. elegans (Burbea et al. 2002). In this study, Burbea et 
al. show that GLR-1, a subunit of APMARs, can be ubiquinated in vivo, resulting in a 
down-regulation of Ubi overexpression on synaptic spine density and changes in synaptic 
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structure and function. Another research study indicates that AMPAR turnover is affected 
by the activity of Na, K-ATPase (NKA) and is achieved through a proteasome-dependent 
process (Zhang et al. 2009). The inhibition of NKA reduces the expression of AMPARs, 
both on surface and in total level, while the inhibition of proteasome can block this 
reduction of AMPARs, indicating that UPS is an important mechanism in this process. In 
addition, the AMPAR degradation has been found in highly activated single synapses 
(Hou et al. 2011). Consistent with Zhang et al.’s work, the loss of AMPARs can also 
been prevented by proteasome inhibitors. One later study has found that the Nedd4, a 
member of E3 ligase that can specifically recognize GluA1, is necessary for AMPAR 
ubiquitination (Lin et al. 2011). Nedd4 co-localizes with AMPARs at synapses and 
enhances the ubiquitination of AMPARs, resulting in AMPAR internalization and 
reduced surface expression. More recently, it has been shown that all AMPAR subunits 
GluA1, GluA2, GluA3, and GluA4, can be ubiquitinated in an activity-dependent manner 
(Widagdo et al. 2015). In addition, major ubiquitination sites of GluA1 and GluA2 on 
their C-terminal lysines, K868 and K870/K882, have also been identified (Lin	 et	 al.	2011,	 Widagdo	 et	 al.	 2015).	 Mutations of lysine residues on these sites reduce the 
ubiquitination of AMPARs and prevent the further degradation of AMPARs. On the 
other hand, USP46, a specific DUB enzyme of USP family, appears to be involved in 
AMPAR deubiquitination. Overexpression of USP46 decreases the ubiquitination of 
AMPARs and leads to AMPAR accumulation, while USP46 knockdown shows an 
increasing level of APMARs (Huo et al. 2015). These studies all suggest the 
ubiquitination-proteasome pathway is crucial for the regulation of AMPARs.  
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1.4 Current study  
Increasing evidence has shown that UBQLNs play a critical in many 
neurodegenerative diseases like Alzheimer’s disease (AD) and amyotrophic lateral 
sclerosis (ALS). A recently study shows that UBQLN1 inhibits the maturation of full-
length amyloid precursor protein (APP) by regulating its trafficking and degradation, 
which reduces the production of amyloid-beta (Aβ) and contributes to a protective 
mechanism of AD (El Ayadi et al. 2012). However, one study shows that overexpression 
of UBQLN in Drosophila causes retinal degeneration (Ganguly et al. 2008), indicating 
that increased levels of UBQLN can be cytotoxic. Mutations of UBQLN genes have also 
been linked to the genesis of neurodegenerative diseases. Several mutant genes encoding 
UBQLN2 may be implicated in the development of ALS and frontotemporal type of 
dementia (ALS-FTD) (Williams et al. 2012).  
 
Based the findings from these studies, it is evident that dysfunction or mutation of 
UBQLN may cause aberrant protein aggregation while the overexpression of UBQLN 
may cause abnormal protein degradation. In the present study, we hypothesize that 
UBQLN plays an important role in AMPAR regulation. Since UBQLN can physically 
associate with Ubi-chains and the 26S proteasome and also mediate protein degradation, 
we hypothesize that UBQLN can interact with ubiquitinated APMARs and thus regulate 
AMPAR degradation through the UPS pathway. We used cultured hippocampal neurons 
and HEK 293T cells to elucidate the functions of UBQLN and explore potential 
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underlying mechanisms of the UBQLN involvement in neurodegenerative diseases.  
 
 
Fig. 3 An illustration elucidates our hypothesis. The GluA1 specific E3 ligase Nedd4 
facilitates the AMPAR ubiquitination. After the AMPAR subunit has been tagged with 
Ubi-chain, UBQLN bind to the Ubi-chain on GluA1 via its UBA domain and the 
proteasome via the UBL domain, working as a bridge to transfer the ubiquinated 
AMPAR to the proteasome for further degradation.   
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2. METHODS  
 
2.1 Primary cultured neurons and HEK 293T cells  
Cortical and hippocampal brain tissues were dissected from embryonic day 18 (E18) 
rat embryos of either sex and were prepared for primary culture. Tissues were first 
digested with papain (0.5 mg/ml in HBSS) at 37 ℃ for 20 min, and then gently triturated 
with a Pasteur pipette in trituration buffer (0.1% DNase, 1% ovomucoid/1% bovine 
serum albumin in HBSS) until neurons were fully dissociated. Dissociated cortical 
neurons were then counted and plated into either 6-well plates or 60 mm Petri dishes 
(Greiner Cellstar). Hippocampal neurons were plated on 18 mm circular coverslips 
(Carolina, 0.1 mm thick) in 60 mm Petri dishes (5 coverslips/dish). Both dishes and 
coverslips were coated with poly-L-lysine (SigmaeAldrich, 100 mg/ml in Borate buffer) 
overnight at 37 ℃ then washed three times with sterile DI water and left in plating 
medium [DMEM containing 10% fetal bovine serum (FBS), 5% horse serum (HS), 31 
mg L-cysteine, and 1% penicillin/streptomycin and L-glutamine mixture (1% P/S/G); 
Invitrogen] before cell plating. Plating medium was then replaced by feeding medium 
(Neurobasal medium supplemented with 1% HS, 2% B-27 and 1% P/ S/G) the day after 
cell plating. Neurons were maintained in feeding medium with FDU (10 mM) 
supplemented at day 5 in vitro (DIV5) to suppress glial growth until experimental use.  
Human embryonic kidney (HEK) 293T cells were cultured in Dulbecco’s Modified 
Eagle Medium (Gibco) supplemented with 10% heat-inactivated fetal bovine serum and 
1% penicillin/streptomycin. HEK cells were split into 6-well plates (1 million/well) or 
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6cm dishes (2 million/well) to grow overnight prior to transfection.  
 
2.2 Neuronal and HEK 293T cell transfection  
Transfections on cultured neurons were performed with Lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA), according to manufacturer’s instructions. Two days 
following transfection, cells were immunostained or lysed for biochemical analysis.  
HEK 293T cells were cultured and split into 6-well plates (1 million/well) or 6cm 
dishes (2 million/well) to grow overnight prior to transfection. Transfections were 
performed at approximately 50-70% confluency. The transfection process for HEK 293T 
cells is identical to that described for neurons except that 4 mL Lipofectamine 2000 was 
mixed with target plasmid to transfect each well of cells. Medium was changed 4 h post-
transfection and HEK 293T cells were further cultured an additional 24-48 h to ensure 
target protein expressions before cells were harvested for Western blot analysis. HEK 
293T cells were cultured in the following medium: 1X DMEM with 10% FBS, 1% P/S 
and 1% L-Glutamine.  
 
2.3 Immunocytochemistry 
Low-density (54,000/coverslip) hippocampal neurons were washed once in ACSF 
and fixed for 10 min in 4% paraformaldehyde/4% sucrose solution on ice. To stain total 
protein, cell membranes were permeabilized for 10 min in 0.3% Triton-X-100 
(FisherBiotech) in phosphate buffered saline (PBS), rinsed three times in PBS, and then 
subjected to a 1 h blocking procedure (5% goat serum in PBS). After blocking, cells were 
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incubated with primary antibodies (in 5% goat serum in PBS) for 2 h, washed with PBS, 
and then incubated with Alexa Fluor-conjugated fluorescent secondary anti-bodies 
(1:700, Life Technologies) for 1 h. Cells were then mounted to microscopy glass slides 
with Prolong Gold anti-fade mounting reagent (Life Technologies) for subsequent 
visualization. 
 
2.4 Neuronal cell image collection and analysis  
Immunostained coverslips were mounted onto slides with Prolong Gold Antifade 
reagent (Invitrogen) and kept in the dark for at least 24 h before imaging. Using a Carl 
Zeiss inverted fluorescent microscope, neuronal cell images were collected with a 63 oil-
immersion objective (numerical aperture, 1.4) and collected with AxioVision Release 4.5 
software. The exposure time of the fluorescence signal was adjusted manually to ensure 
that the signal intensity was within the full dynamic range by using a glow scale look-up 
table. Once an exposure time was established, it was employed throughout the whole 
image collection process for all samples. Neuron images were quantified using NIH 
ImageJ. For quantification, GluA1 puncta ranging in size from 3-55 pixels were first 
selected using a thresholding function before both mean puncta size and intensity were 
automatically measured. GluA1 total intensity was calculated by multiplying the value 
obtained for mean puncta size by the value obtained for fluorescence intensity after 
subtracting the background value of each picture.  
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2.5 Western blot analysis of protein abundance 
Cells in control groups were treated with the appropriate vehicle solvents (saline or 
DMSO). After treatment, neurons were lysed in Laemmli 2X sample buffer (4% SDS, 
10% 2- mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, 0.125 M Tris HCl) 
and boiled for 10-min at 95 ℃ for SDS page electrophoresis. After separation in SDS 
page, proteins were transferred to PVDF immunoblotting membrane (Bio-rad) and 
probed for different targets with the stated antibodies. Immunoblots were visualized using 
a chemiluminescence detection system (GE Healthcare) and exposed to Fuji medical X-
ray films (Fisher Scientific), scanned and analyzed using the NIH ImageJ program.  
 
2.6 Co-Immunoprecipitation and Western blot analysis 
Cells were rinsed with cold PBS and resuspended in 100–200 μL modified 
radioimmunoprecipitation assay lysis buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl, 
1% NP-40 (Affymetrix/USB, Santa Clara, CA, USA), 1% SDOC and 0.1% SDS) 
containing mini complete protease inhibitor (Roche, Indianapolis, IN, USA) and 5 μM 
ubiquitin aldehyde (Sigma, St Louis, MO, USA) to inhibit deubiquitination. Lysates were 
further solubilized by sonication and 10 min incubation on ice followed by centrifugation 
for 10 min at 13 000 g to remove insolubilities. Supernatant volumes were adjusted to 
500 μL with NP-40 buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 5 mM EDTA and 1% 
NP-40 plus mini complete and 5 μM ubiquitin aldehyde) and incubated overnight for 8–
12 h on rotation at 4°C with protein A-Sepharose beads (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) and antibodies against GluA1.  
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2.7 Data analysis 
All values are presented as mean ± S.E. and analyzed using Student's t-test to 
compare the statistical difference between control and treatment groups. n indicates the 
number of independent experiments and samples in Western blots, or the number of cells 
in immunostaining assays. p < 0.05 is considered as statistically significant. p values are 
presented as p > 0.05, 0.01 < p < 0.05, or p < 0.01.  
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3. RESULTS 
 
3.1 Overexpression of UBQLN facilitates GluA1 degradation  
To investigate the effects of overexpression of UBQLN on AMPAR expression, 
DIV11 cultured hippocampal neurons were transfected with EGFP, together with or 
without UBQLN, for 4 h. Three days after the transfection, the GluA1 density and 
intensity on dendrites were analyzed. We found that the overexpression of UBQLN 
decreases the GluA1 levels on dendrites, while no significant morphological changes 
were been found (Fig. 4). The AMPAR levels were indicated by the intensity and density 
of GluA1. Intensity was measured by the puncta size multiplied by the fluorescence value 
(Fig. 5 A), which could reflect the protein level and synaptic strength. Density was 
measured by the numbers of puncta density within a certain length of the dendrite (Fig. 5 
B). To examine the effect of UBQLN overexpression on overall GluA1 level, HEK 293T 
cells were transfected with AMPAR subunit GluA1 with or without UBQLN. Consistent 
with the immunostaining results in neurons, we found that the total protein level of 
GluA1 also decreased when UBQLN was overexpressed (Fig.5 C and D), indicating that 
UBQLN enhance the AMPAR degradation, resulting in an overall expression reduction 
in vitro.  
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Fig. 4 Overexpression of UBQLN reduces AMPAR abundance in neurons. Cultured 
DIV11 hippocampal neurons were transfected with empty vectors (left column) or 
UBQLN-GFP (right column) as well as EGFP (green signals), and immunostained with 
anti-GluA1 (red signals) antibodies at DIV14. Scale bar: 20 μm.  
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Fig. 5 (A) Measurement of GluA1 puncta intensity showed significantly reduction in 
UBQLN overexpressed neurons (Ctrl: 843.186 ± 35.138, n=15 cells; UBQLN: 672.257 ± 
30.616, n=12 cells **p < 0.01, t-test). (B) The intensity of GluA1 significantly reduced in 
UBQLN overexpressed neurons (Ctrl: 0.061 ± 0.005, n=15 cells; UBQLN: 0.045 ± 0.003, 
n=12 cells *p < 0.05, t-test). (C and D) HEK293A cells were transfected with empty 
vector or UBQLN-GFP to confirmation of the effect of UBQLN overexpression. Cell 
lysates prepared two days after transfection were subject to Western blotting analysis. 
GluA1 expression was significantly reduced with the over-expression of UBQLN (Ctrl: 
0.997 ± 0.048; UBQLN: 0.727 ± 0.061. n = 4, independent experiments. **p < 0.01, t-
test).   
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3.2 UBQLN co-distributes and interacts with AMPAR subunit  
To investigate the co-localization between UBQLN and AMPARs, double 
immunostaining was conducted in hippocampal neurons with GluA1-N-terminal 
antibodies and UBQLN antibodies (Fig. 6 A). Results showed co-localization of GluA1 
and UBQNL in neuron spines, indicating that there is interaction between AMPAR 
GluA1 and UBQLN in neuronal dendrites.  
According to our hypothesis, UBQLN facilitates the ubiquinated GluA1 to 
proteasomal degradation by transferring the substrate to the proteasome. To examine if 
UBQLN is capable of interacting with its substrate, GluA1 was co-expressed together 
with UBQLN in HEK 293T cells. Two days after transfection, GluA1 subunits were 
immunoprecipitated with anti-GluA1 antibodies and anti-UBQLN antibodies were used 
to detect their interaction. Results indicated a clear interaction between GluA1 and 
UBQLN (Fig. 6 B).  
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Fig. 6 UBQLN localizes at synapses and associates with AMPAR subunit GluA1. (A) 
Double staining with anti-GluA1 and anti-UBQLN antibodies in hippocampal neurons 
indicates co-localization of UBQLN with AMPAR GluA1. The boxed area is enlarged 
for clarity. Arrows indicate puncta of co-distribution. Scale bar: 20 μm. (B) Western blots 
of Co-immunoprecipitation prepared from HEK 293T cells. Using lysates from rat 
primary culture, UBQLN was detected in co-immunoprecipitates of anti-UBQLN 
antibodies, indicating association with GluA1. Reprobing of the membrane with anti-
GluA1 antibodies confirmed the specific pull-down of GluA1 (top panel).   
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3.3 UBQLN facilitates GluA1 degradation through the Ubi-proteasome pathway 
To further confirm that ubiquitination of GluA1 is necessary for GluA1 to bind with 
UBQLN, the effects of the KR mutations of GluA1 on the interaction between GluA1 
and UBQLN were evaluated. HEK 293T cells were co-transfected with either wild type 
GluA1 (WT-GluA1) or K868R mutant GluA1 (GluA1-K868), together with or without 
UBQLN, and were immunoprecipitated with anti-GluA1 antibodies. After two days 
transfection, cell lysates were prepared in a denaturing lysis buffer and were 
immunoprecipitated with anti-GluA1. The interaction between GluA1 and UBQLN was 
probed with anti-UBQLN antibodies (Fig. 7). We found that UBQLN overexpression 
reduced the total GluA1 level in cell lysis in both WT groups and K868 groups. In the 
K868 mutant groups, but the change in K868 groups has no statistic significance (Fig. 8 
A). Despite a weak interaction persisting in the K868 mutant GluA1 group, the 
interaction between GluA1 and UBQLN was significantly less than that in WT-GluA1 
group. UBQLN interaction signals were normalized to GluA1 protein pull-down amount 
(Fig. 8 B). The results show that the K868 mutant reduces the interaction between GluA1 
and UBQLN, indicating that GluA1 ubiquitination is important to the binding between 
GluA1 and UBQLN.  
Additionally, the effect of ubiquitination level on the interaction between GluA1 and 
UBQLN was explored. Nedd4 is an E3 ligase that can specifically recognize GluA1 and 
increase the ubiquination of GluA1. Our results showed that the total GluA1 levels were 
decreased in the UBQLN group compared to the control group, but no difference in cells 
		
26		 	 	
co-expressing with UBQLN and Nedd4 were found (Fig 9 A). However, the interaction 
between UBQLN and GluA1 showed a significant increase in the presence of Nedd4 (Fig. 
9 B).  
 
 
Fig. 7 The K868 mutant GluA1 has less interaction between UBQLN and GluA1. HEK 
293T cells were transfected with WT-GluA1 or GluA1-K868, with or without UBQLN. 
Total GluA1 levels were probed in input samples. Lysate tubulin was probed as a loading 
control. The same Western blot was reprobed to confirm pull-down of GluA1.   
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Fig. 8 (A) UBQLN overexpression can reduce the GluA1 level in cell lysis (WT: 0.861 ± 
0.119; WT+UBQLN: 0.517 ± 0.119. n = 3, independent experiments. *p < 0.05, t-test). In 
the K868 mutant groups, the total GluA1 expressions also show a decreasing trend, but 
without statistic significance. (K868: 0.803 ± 0.153; K868+UBQLN: 0.727 ± 0.091. n = 
3, independent experiments. p > 0.05, t-test). (B) Quantification of the interaction 
intensity. All the signals were standardized by GluA1 pull-down intensity (WT+UBQLN: 
0.826 ± 0.251; K868+UBQLN: 0.245 ± 0.121. n = 3, independent experiments. *p < 
0.05, t-test).  
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Fig. 9 The presence of Nedd4 increases the interaction between UBQLN and GluA1. (A) 
HEK 293T cells were transfected as indicated in the chart. Total GluA1 levels were 
probed in input samples (left top panel). Lysate tubulin was probed as a loading control 
(left bottom panel). The same Western blot was reprobed to confirm pull-down of GluA1 
(right top panel). (B) Quantification of the interaction intensity. All the signals were 
standardized by GluA1 pull-down intensity (UBQLN: 0.360 ± 0.020; UBQLN+Nedd4: 
0.538 ± 0.072. n = 3, independent experiments. *p < 0.05, t-test).  
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3.4 UBQLN2 has a higher expression in AD patient brain 
To explore the potential mechanisms of neurodegenerative disease, GluA1 and 
UBQLN2 protein levels were measured in brain lysis samples of healthy people and AD 
patients, from prefrontal cortex (PFC) and hippocampus (Hippo). The UBQLN2 and 
GluA1 signals were normalized by tubulin expression (Fig. 10 A). Although there were 
variations among different samples, the quantified results revealed that the UBQLN 
levels in AD brains were higher than that of the control group, especially in the PFC, 
where high-level brain function occurs (Fig. 10 B). On the other hand, GluA1 levels were 
much lower in the AD group compared to the control group. These results suggest a 
potential relationship between increased UBQLN levels and decreased AMPAR levels in 
AD patients compared to healthy controls (Fig. 10 C).  
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Fig. 10 The expressions of UBQLN2 and GluA1 in AD patient brain. (A) Brain lysis 
samples from normal people and AD patients were examined using Western blotting. 
Two different regions were investigated: the prefrontal cortex (PFC) and hippocampus 
(Hippo). The same blot was probed for UBQLN2 and GluA1 antibodies. Tubulin was 
also probed as a loading control. (B) Quantification of UBQLN2 and GluA1 signals. All 
the signals were standardized by tubulin. The UBQLN2 levels show increase in both PFC 
(Ctrl: 0.039 ± 0.016; AD: 0.084 ± 0.014. n = 3, independent samples. *p < 0.05, t-test.) 
and hippocampus (Ctrl: 0.213 ± 0.053; AD: 0.337 ± 0.178. n = 3, independent samples. p 
> 0.05, t-test.) but was not significant in hippocampus. The GluA1 expressions show 
significant reduction in both PFC (Ctrl: 0.223 ± 0.031; AD: 0.152 ± 0.015. n = 3, 
independent samples. *p < 0.05, t-test.) and hippocampus (Ctrl: 0.704 ± 0.104; AD: 0.227 
± 0.147. n = 3, independent samples. **p < 0.01, t-test).  
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4. DISCUSSION 
 
4.1 AMPAR abundance and UBQLN expression 
AMPARs are a crucial for excitatory synaptic neurotransmission in the CNS. A 
hallmark of many neurodegenerative diseases, such as AD, ALS, and Huntington disease, 
is a reduction of AMPAR abundance, resulting in dysfunction of synapses and 
impairment in the whole brain activities (Huganir and Nicoll 2013). In the present study, 
we find that the overexpression of UBQLN in HEK 293T cell can enhance the 
degradation of AMPARs. In line with the results in immunostaining in hippocampal 
neurons, overexpressing UBQLN was found to reduce total AMPAR abundance on 
dendrites, measured by both the number of puncta and the intensity of GluA1.  
Recently, UBQLN has been shown to have disparate effects on degradation of 
different proteins in previous studies. In Ganguly et al.’s study, UBQLN was 
overexpressed in young adult flies and the effects at different time points were recorded. 
The results indicate that UBQLN has no significant changes in the early development and 
tissue morphology at early stage but does show obvious degenerations in photoreceptors 
and pigment cells (Ganguly et al. 2008). This research is consistent with our results that 
overexpression of UBQLN can enhance the protein degradation. However, overexpressed 
UBQLN has also shown to reduce on the efficiency of proteasomal degradation for other 
proteins, including p53, IκBα, presenilin proteins, and GABAA receptors (Kleijnen et al. 
2000, Bedford et al. 2001).  
According to all the studies above, UBQLN seems like to play a complicated role in 
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the ubiquitin-dependent degradation and to affect different protein levels in a substrate-
specific manner. As for AMPARs, UBQLN can form a compound with AMPARs and 
enhance the degradation. However, our research is only based on overexpression of 
UBQLN. Further experiments such as UBQLN knockdown exploration could be done to 
confirm the necessity of UBQLN in AMPAR degradation.  
 
4.2 The interaction between UBQLN and GluA1 is Ubi-dependent  
Previous studies have shown an association of UBQLN with many components of 
UPS, suggesting an important role for UBQLN in ubiquitin-proteasome degradation. 
Specific ubiquitination sites of AMPAR have been identified. Ubi-chains can tag to all 
four lysine residues of GluA1 at the intracellular C-terminus, but target lysine 868 and 
Lys-870/Lys-882 as major ubiquitination sites. Mutations of these residues significantly 
reduce GluA1 ubiquitination (Lin et al. 2011, Widagdo et al. 2015).  
In our study, we confirm the interaction between UBQLN and AMPAR subunit 
GluA1 both in vivo and in vitro. We then compare effects of UBQLN overexpression on 
the WT-GluA1 and K886 mutant GluA1. It is consistent with our previous results that 
UBQLN overexpression can reduce the GluA1 level in cell lysis. In the K868 mutant 
groups, the total GluA1 expressions also showed a modest but non-significant reduction. 
We also find that the K868 mutant GluA1 has less interaction with UBQLN than the WT-
GluA1, indicating that the interaction between GluA1 and UBQNL correlates to the 
ubiquitination of GluA1.  
The decrease of total GluA1 in K868 mutant groups may be due to the incomplete 
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deletion of GluA1 ubiquitination, where one single site mutant may reduce the 
ubiquitination of GluA1, but Ubi-chains may still bind to GluA1 at other residues. 
Similarly, decreased interaction between UBQLN and GluA1-K868 can be explained by 
less extensive ubiquitination at GluA1-K868. Alternatively, the decrease of total GluA1-
K868 due to UBQLN overexpression may be explained by the existence other pathways 
besides the UPS are involved in AMPAR degradation. Previous research has indicated 
that UBQLN is involved in the process of autophagy, including the interaction with 
mictotubule-associated protein 1 light chain 3 and the formation of autophagic vacuoles 
(N'Diaye et al. 2009). A recent study also demonstrated the degradation of internalized 
AMPARs regulated by the neuronal activity can be achieved through the lysosome 
degradation pathway (Shehata et al. 2012). Thus, the reduction of total GluA1 in K868 
mutant group may result from the involvement of autophagy in the degradation of 
AMPARs.  
We also overexpressed Nedd4 to further confirm the Ubi-dependent interaction. Our 
results show a significant increase in the binding between UBQLN and GluA1in the 
presence of Nedd4. Interestingly, compared to the control group, the total GluA1 levels 
decrease with the overexpression of UBQLN, but no difference with co-expression of 
UBQLN and Nedd4. Our results indicate that expression of Nedd4 can reverse the GluA1 
reduction caused by UBQLN overexpression. A similar result was found in previous 
study, showing that Nedd4 overexpression in neurons decreases surface AMPAR 
expression without changing the total receptor amount (Lin et al., 2011). Nedd4 has also 
been shown to be able to get into nuclei and to regulate nuclear targets (Hamilton et al. 
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2001). Thus, the total GluA1 level with Nedd4 overexpression may results from multiple 
functions of Nedd4, such as increasing the AMPAR genes transcription or translation, 
which may counterbalance the AMPAR degradation and result in a similar level of total 
AMPAR expression.  
In addition, we explored the effect of co-expression with UBQLN and Ubi protein. 
We found that when Ubi is overexpressed, there is a lower level of the interaction 
between UBQLN and GluA1 (data is not shown here). Since the UBA domain of 
UBQLN can bind to the Ubi-chain, it is possible that excess free ubiquitin protein can 
occupy the UBA domains on UBQLN, blocking the binding sites on UBQLN and 
preventing the interaction with the Ubi-chains of the ubiquinated GluA1. Based upon 
these results, we propose that high amounts of UBQLN in cells enhance the binding with 
the ubiquinated GluA1 via the UBA domain and facilitate transferring the ubiquinated 
GluA1 to the proteasome for degradation.  
 
4.3 UBQLN and neurodegenerative diseases  
Significant reductions of AMPARs on synaptic membranes as well as different 
regions in brain has been reported in AD patients (Carter et al. 2004). The smaller spine 
areas and less puncta numbers of AMPARs can represent a lower level of synaptic 
functions (Harris et al. 1992, Matsuzaki et al. 2001, Kasai et al. 2010). Recently, a new 
study has demonstrated that Aβ can enhance the ubiquitination of AMPARs, induces the 
redistribution and recruitment of Nedd4, and decreases surface AMPARs (Rodrigues et 
al. 2016). Consistent with the findings of these studies, our results show a significant 
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reduction of APMARs in AD patient brain samples, indicating that dysfunction of 
AMPAR degradation and trafficking may contribute to AD genesis and development.  
In our study, significant reductions in AMPAR expression and also increasing levels 
of UBQLN2 have been found in AD brains, especially in the prefrontal cortex region. 
However, another study shows a reduced level of UBQLN2 in AD patients (Tanaka and 
Matsuda 2014). In this study, the authors show a decrease in UBQLN2 protein level but 
no difference in mRNA level, neither in the hippocampus nor in the cortex. The results 
also indicate a lack of connection between UBQLN2 and tau-pathology (Nölle et al. 
2013). In our study, we found a higher level of UBQLN2, which, according to our 
hypothesis, might be potential mechanisms of the reduction of AMPARs in AD instead of 
tau-pathology. We propose that the increased level of UBQLN2 found in the AD brains 
may enhance the ubiquitination and degradation of AMPARs, contributing to the synaptic 
dysfunction and progressive cognitive decline associated with the disease.  
There are now many studies that focus on the relationship between UBQLN 
dysfunction and protein aggregation in neurodegenerative disorders, but the underlying 
mechanisms of protein aggregation remain unclear. In recent years, increasing evidence 
has indicated that UBQLN1 is involved in the development of AD by affecting the 
aggregation of several proteins that are related to the neurodegeneration. One study 
shows that UBQLN1 inhibits the maturation of APP and delays the further process 
(Takalo et al. 2013). The UBQLN has also been shown to interact with presenilin-1 and 
presenilin-2, leading to an accumulation of presenilin (Arias-Vasquez et al. 2007). 
However, overexpression of UBQLN in Drosophila has also been shown to cause retinal 
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degeneration (Ganguly et al. 2008), indicating that overexpression of UBQLN may also 
contribute to neurodegeneration by inducing protein degradation (Ganguly et al. 2008). 
Our study indicates the UBQLN can reduce the AMPAR abundance. Based on these 
studies, UBQLN seem to be involved in both proteins aggregation and degradation.  
In addition to its possible role in the development of AD, UBQLN2 is also involved 
in ALS. Genetic studies have shown the relation between UBQLN2 mutations and ALS, 
both in familial and sporadic ALS. So far, five mutations in UBQLN2 have been 
reported, providing strong evidence for the involvement of protein degradation in 
neurodegenerative diseases (Deng et al. 2011, Xia et al. 2014). More findings suggest 
that  the higher level of GluA2-lacking, Ca2+ permeable AMPARs (Cp-AMPARs), may 
contribute to the development of ALS (Kwak and Weiss 2006). In normal condition, 
there are some transient expressions of Cp-AMPARs within certain time and regions, 
which may be important for the normal synaptic development and signaling regulation 
(Man 2011). Other studies also propose that motor neuron degeneration in ALS can be 
linked to an abnormal expression of Cp-AMPARs, leading to a metabolic disorder and 
further degeneration of neurons in the CNS (Kwak and Weiss 2006). So far, it is still 
unclear whether the mutations of UBQLN2 can result in a loss of protein functions or 
toxic functions. One possible mechanism, based on our findings, is that defects in 
UBQLN2 may interrupt the degradation of GluA1 and thus result in an imbalance 
between GluA1 and GluA2 and more Cp-AMPARs. Other experiments, such as the 
effects of the mutation genes on GluA1 and GluA2 expressions and also neuronal 
functional examinations should be done to further elucidate the mechanisms of UBQLN 
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in ALS pathology.  
 Overall, it is evident that UBQLN might have both protective functions and 
pathogenic capabilities in causing protein aggregation and degradation. Although the 
exact role of UBQLN in neurodegenerative disorders remains to be elucidated, it is 
possible that the down-regulation of AMPARs by UBQLN play an important role in the 
generation and development of neurodegenerative diseases.  
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